228 Anxiety Disorders
arately (e.g., 292.89 methylphenidate-induced an xiety disorder, with on set during intoxica-
tion; 292.89 salbutamol-induced anxiety di sorder, with onset after medication use).
ICD-10-CM. The name of the substance/medication-induced anxiety disorder begins
with the specific substance (e.g ., cocaine, salbutamol) that is  presumed to be causing the
anxiety symptoms. The di agnostic code is selected from the table included in the criteria
set, which is based on the drug class and presence or absence of a comorbid substance use
disorder. For substances that do not fit into any of the classes (e.g., salbutamol), the code
for “other substance” should be used; and in cases in which a substance is judged to be an
etiological factor but the specific class of substance is unknown, the category “unknown
substance” should be used.
When recording the name of the disorder, th e comorbid substance use disorder (if any)
is listed first, followed by the word “with,” followed by the name of the substance-induced
anxiety disorder, followed by the specification of onset (i.e., onset during intoxication,
onset during withdrawal, with onset during medication use). For example, in the case of
anxiety symptoms occurring during withdrawal  in a man with a severe lorazepam use dis-
order, the diagnosis is F13.280 severe lor azepam use disorder with lorazepam-induced
anxiety disorder, with onset du ring withdrawal. A separate diagnosis of the comorbid se-
vere lorazepam use disorder is not given. If the substance-induced anxiety disorder occurs
without a comorbid substance use disorder (e.g., after a one-time heavy use of the substance),